The 282nd Healthcare Innovation in North America brought together investors, family office representatives, healthcare professionals and technology-focused participants to examine a question that goes beyond whether healthcare innovation exists: what is preventing promising innovation from reaching patients at the speed and scale required?

The discussion revealed a healthcare investment environment shaped by both opportunity and friction. Aging populations and rising healthcare costs are increasing demand for innovation, while capital scarcity, long development timelines, regulatory complexity and fragmented healthcare systems continue to slow progress. At the same time, AI is opening new possibilities in healthcare, while raising questions about how quickly institutions and regulators can adapt.

These challenges are closely connected: promising technologies can face years of development, slow approvals or difficult adoption, while companies with funding can still struggle to navigate the healthcare system and reach patients.

The Commercialization Gap: Innovation Exists, but Speed Matters

The discussion began with one of the most fundamental challenges facing healthcare innovation: the distance between having a promising technology and getting it into the hands of patients. Marc Flohr, Executive Board Member, Family Principal at Mingenta, from Dubai pointed to a lack of access and speed in the U.S. market, particularly around clinical trials and FDA approvals. In his view, the problem is not simply the availability of money; companies can have funding and still lose valuable time navigating the path toward commercialization.

This creates a particular challenge for healthcare investors because development delays extend the period before an investment can demonstrate meaningful progress. Mark also emphasized that many innovations already exist but remain unavailable to patients because of the time required to move through the system. He said, “Although a lot of funding is available, everything takes too long.”

Dr. Frederico Mesquita, Managing Partner at Lotus investment strategies from Finland, added an international perspective, contrasting the development speed of life sciences with faster-moving technology sectors. For investors, the issue becomes particularly important when comparing markets with different clinical and regulatory timelines. He noted that slower development in North America can affect not only companies but also the investors financing them. He said, “Life science is a completely different beast and operates at a completely different speed. As you may know, crypto can move overnight, while life science can take decades, and we are more focused on drug development.”

Capital Is Available - But Not Equally Available

Capital scarcity emerged as one of the clearest themes of the discussion. Participants pointed out that promising startups and SMEs can have strong research or development portfolios while still lacking the money required to develop, scale and commercialize their technologies. At the same time, capital is increasingly concentrated around certain areas of the market, particularly AI and growth-stage companies.

Anneliese Sound, Managing Director at Future Potential Management, from Germany emphasized that investors need to look beyond short-term market activity. For healthcare in particular, where development cycles can be long, the distinction between temporary market enthusiasm and opportunities capable of producing value over a longer period becomes increasingly important. He said, “We have to sort out this very active noise at the moment and have to look at a more long term Investment scheme where I do see some issues.”

Mark Wesson, Venture Partner at Global Health Impact Network & Funds, from the United States built on this point from the perspective of healthcare services and early-stage development. He described capital being pulled away from the market while also highlighting another challenge: healthcare institutions may have access to information and technology without necessarily having the internal consensus required to act on it. He said, “I would say some of the more, some of the more very clear, you know, some of the clearer challenges that I see at the moment are the capital being sucked out of the room.”

The result is a more selective environment in which investors must consider not only whether an opportunity is attractive, but whether it can survive the time and capital requirements of healthcare development.

What Makes a Healthcare Opportunity Investable?

As the conversation moved from market conditions toward investment decisions, participants discussed the increasing importance of evidence and traction. Robert Herzog, Managing Partner at Breaking Wave Capital, from the United States explained that his investment process encounters many healthcare businesses addressing narrow problems, but that later-stage investors require more than an interesting concept. Proof of concept, traction and revenue become increasingly important as companies approach institutional financing rounds.

This changes the way healthcare opportunities are evaluated. Scientific potential remains important, but investors also need evidence that a technology can operate in a real market, gain adoption and develop into a commercially sustainable business. The ability to demonstrate progress therefore becomes an important bridge between early innovation and later-stage capital. He said, “We want to see proof of concept. We want to see traction. We want to see some reasonable revenue.”

Healthcare's Structural Problem: Innovation Meets Fragmentation

Technology does not enter an empty market. It has to operate within a healthcare system involving patients, providers, payers, hospitals, regulators and multiple financial incentives. Russell Findlay, CEO of Swellaway from the United States described this structure as one of the major obstacles to rapid innovation in the U.S., pointing to fragmentation and incentives that do not always align across participants in the system.

This fragmentation has investment consequences. A technology can create value for patients while creating different financial or operational consequences for providers and corporations. For companies attempting to introduce significant changes, this can make adoption slower and more incremental than the technology itself might suggest. He said, “And there's innovation for profit versus innovation for recovery. And what's good for the patient is not necessarily good for the provider or good for the corporation.”

Russell also connected the structural challenge with healthcare workforce pressure. Employee burnout increases the demand for technologies that can reduce workload, but adoption becomes more difficult when a solution requires major changes to already-stretched organizations.

AI Is Advancing Faster Than Healthcare Can Absorb It

Artificial intelligence became one of the clearest areas where technological progress and healthcare's existing structures came into conflict. Ian Valentine, a private investor from the United Kingdom focused specifically on the intersection between AI and drug discovery, arguing that the science is progressing while regulatory frameworks have not yet fully adapted to the new models being developed.

AI can potentially allow researchers to test and model biological effects before moving through every traditional stage of experimentation. However, for these approaches to meaningfully shorten development timelines, regulators need confidence in the models and the data they generate. He said,“And I think the thing that excites me is drug discovery overlapping with AI and the fact that the regulatory framework that we've talked about already amongst some of the participants is actually the thing that's holding back progress now. Not, not the science. Science can be done.”

This creates an important distinction for investors: AI may improve the underlying development process, but technological capability alone does not determine how quickly a healthcare innovation reaches the market. Regulatory acceptance, clinical validation and institutional adoption remain essential parts of the investment equation.

Funding the Journey from Research to Commercialization

The later discussion returned to the question of where early healthcare innovation gets its capital. Omid Akhavan, Managing Director at Anthro Ventures, from the United States described disruptions affecting traditional public funding mechanisms that have historically helped incubate early-stage technologies. While alternative grant mechanisms continue to provide funding, the overall environment has made early-stage risk more difficult to justify.

His comments also illustrated how the funding environment can influence investor strategy. As the risk and cost of early development increase, some investors are placing greater emphasis on opportunities closer to commercialization, where there is more evidence of market readiness and a shorter path to revenue. He said,“But I think for most early stage startups, you know, I think lack of access to that funding and then the risk free rate being over 5% now with bond yields going up, I think just makes it difficult to want to take that early stage risk.”

Omid described this as part of a broader shift in his own investment approach, from a greater emphasis on clinical-stage opportunities toward commercial-stage healthcare opportunities. This reflects the wider discussion around the importance of commercialization, traction and capital efficiency in the current environment.

The Investment Market Is Also Being Shaped by AI Capital Concentration

The discussion also considered how broader investment trends are influencing healthcare. Tony Jarrin, President & CEO at The Cannaregio Group, from the United States observed that the strong focus on technology and AI over the preceding period has affected where investor attention and capital are directed. For healthcare companies outside the most visible technology trends, this can create an additional challenge in competing for investor attention. He said,“I think that probably the biggest constraint is what we've felt across many sectors is that there's been a heavy focus in tech space and AI.”

This does not mean that AI and healthcare technology are competing against each other in simple terms. Rather, the discussion suggested that investors are operating in an environment where attention, capital and expectations are increasingly concentrated around particular themes, making disciplined evaluation of healthcare opportunities even more important.

Key Themes from the 282nd Healthcare Innovation Summit

The discussion provided a clear view of the factors shaping healthcare opportunities today - from capital flows and early-stage company evaluation to regulation, AI and longer development cycles - while highlighting the challenges companies must overcome before reaching the market and the importance of balancing scientific potential with commercialization, market conditions, regulatory pathways and scalability.